Overview

Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression

Status:
Completed
Trial end date:
2019-07-07
Target enrollment:
Participant gender:
Summary
Randomized, two-part, placebo-controlled study of single ascending doses of NV-5138 in healthy volunteers, and a single dose of NV-5138 in subjects with Treatment-Resistant Depression (TRD)
Phase:
Phase 1
Details
Lead Sponsor:
Navitor Pharmaceuticals, Inc.